Drugs / MNK-1411
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03400852 | Jul 2018 → Feb 2020 | Duchenne muscular dystrophy | Mallinckrodt | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNK-1411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03400852 ↗ |
| Route | Subcutaneous | “for subcutaneous injection” NCT03400852 ↗ |